论文部分内容阅读
目的探讨非瓣膜心房颤动(NVAF)患者血浆分子标志物凝血酶-抗凝血酶Ⅲ(TAT)、vWF浓度变化及其价值。方法研究期间,外周动脉明确存在血栓栓塞并发症的NVAF患者8例为栓塞组;排除外周动脉血栓栓塞并发症的NVAF患者24例为房颤组,对照组25例为无房颤组。各组均分别采用酶联免疫双抗体夹心法(ELISA)测定血浆TAT、vWF活性,对其结果进行对比分析。结果NVAF患者无论是否存在血栓栓塞并发症,其TAT及vWF含量均明显高于无房颤组(P<0.05)。栓塞组患者TAT、vWF水平明显高于房颤组(P均<0.05)。结论房颤可引起凝血系统的激活及内皮系统的损害,检测房颤患者血浆中TAT、vWF可能成为评估房颤患者血栓栓塞危险性的一种有价值的方法。
Objective To investigate the changes and clinical significance of plasma molecular markers thrombin-antithrombin Ⅲ (TAT) and vWF in patients with non-valvular atrial fibrillation (NVAF). During the study period, 8 of the NVAF patients with peripheral thromboembolic complications were identified as embolization group. Among NVAF patients with peripheral arterial thromboembolism complications, 24 were in the AF group and 25 in the control group with no AF. Plasma TAT and vWF activity were measured by enzyme-linked immunosorbent assay (ELISA) in each group, and the results were compared. Results The levels of TAT and vWF in patients with NVAF were significantly higher than those without AF (P <0.05), regardless of the existence of thromboembolic complications. The levels of TAT and vWF in embolism group were significantly higher than those in atrial fibrillation group (all P <0.05). Conclusion Atrial fibrillation can cause activation of the coagulation system and damage to the endothelial system. Detection of plasma TAT and vWF in patients with atrial fibrillation may be a valuable method for assessing the risk of thromboembolism in patients with atrial fibrillation.